PropThink’s Weekly Healthcare Wrap-Up
Most Popular - Pharmacyclics warned in its 3Q earnings release that employees might sell market-moving amounts of shares on Wednesday as they exercised options. As we expected, shares … Continue Reading
Read nowAuthor Archives: Editorial Staff
Weekly Recap: PropThink’s Latest in Healthcare and Biotech
Most Popular - Gilead paid a lot of money – $11B to be exact – to acquire Pharmasset back in 2011. Was it worth it? Propthink dug in … Continue Reading
Read nowPropThink’s Healthcare and Biotech Roundup
Most Popular - Our earnings preview supposed that in-line QCOR earnings could improve share price. QCOR delivered well-above estimates, but shares remained flat following, as reimbursement concerns still linger. … Continue Reading
Read nowIn Healthcare, Passively-Managed Funds May Not Be The Top Investments
Most Popular - The Health Care Select Sector SPDR (XLV), the exchange traded fund (ETF) that tracks the Health Care Select Sector Index, gained $0.03 or 0.07% on … Continue Reading
Read nowPropThink’s Weekly Wrap-Up
Recap - A patent extension for Folotyn added five years to the drug’s market exclusivity and elicited a rally in Spectrum (SPPI) on Monday, but the news … Continue Reading
Read nowARIAD Building an Oncology Business Around Discovery, Development, and Commercialization
Interviews - In an exclusive PropThink interview with ARIAD Pharmaceuticals (NASDAQ:ARIA), CEO Harvey J. Berger discusses the company’s lead product, ponatinib, a potential treatment for intolerant Chronic … Continue Reading
Read nowSickle Cell Drug Finding New Opportunity at ADVENTRX Pharmaceuticals
Interviews - With Orphan Drug status and a largely-unmet medical need for its primary indication, ADVENTRX Pharmaceuticals (AMEX:ANX) expects its lead candidate, ANX-188, to be the company’s … Continue Reading
Read now